XML 55 R55.htm IDEA: XBRL DOCUMENT v2.4.0.8
Fair Value Measurements - Additional Information (Detail) (USD $)
 12 Months Ended 1 Months Ended 12 Months Ended
Sep. 30, 2013
Sep. 30, 2012
Sep. 30, 2011
Sep. 30, 2013
2010 Warrants
Jun. 30, 2010
2010 Warrants
Sep. 30, 2013
2012 Warrants
Dec. 31, 2012
2012 Warrants
Sep. 30, 2013
2013 Warrants
Jan. 31, 2011
Unidym Inc
Sep. 30, 2013
Unidym Inc
Sep. 30, 2013
Ablaris Therapeutics
Fair Value Measurements Disclosure [Line Items]                      
Non cash consideration received in sale of interest in subsidiary, bonds                 $ 2,500,000    
Bond convertible conversion price per share                 $ 2.00    
Gain from change in value of the derivative asset, net of the derivative liability 0                    
Short term investments 9,030,261 106,500                  
Long-term investments 1,702,153                    
Total investments 10,732,414                    
Fair value of investments 10,698,271                    
Bond owed to third party 0 10,646                  
Gain from change in value of the derivative asset                   250,250  
Warrants issued to acquire Common Stock         329,649   912,543 833,530      
Non-cash gain (loss) from change in fair value of the derivative liability 5,066,591                   5,806
Warrants outstanding 4,402,523     187,313   415,761   326,635      
Duration of exchange rights 7 years                    
Exchange right convertible conversion ratio for first year                     0.06
Exchange right convertible conversion ratio for second year                     0.04
Exchange right convertible conversion ratio for third year                     0.03
Exchange right convertible conversion ratio for fourth year                     0.02
Exchange right convertible conversion ratio for fifth year and beyond                     0.01
Number of exchange right sold                     675,000
Contingent consideration $ 1,595,273 $ 173,621